Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation, the addition of midostaurin to standard chemotherapy appeared to improve long-term outcomes.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 377; no. 5; pp. 454 - 464
Main Authors Stone, Richard M, Mandrekar, Sumithra J, Sanford, Ben L, Laumann, Kristina, Geyer, Susan, Bloomfield, Clara D, Thiede, Christian, Prior, Thomas W, Döhner, Konstanze, Marcucci, Guido, Lo-Coco, Francesco, Klisovic, Rebecca B, Wei, Andrew, Sierra, Jorge, Sanz, Miguel A, Brandwein, Joseph M, de Witte, Theo, Niederwieser, Dietger, Appelbaum, Frederick R, Medeiros, Bruno C, Tallman, Martin S, Krauter, Jürgen, Schlenk, Richard F, Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Larson, Richard A, Döhner, Hartmut
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 03.08.2017
Subjects
Acute myeloid leukemia
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Chemotherapy
Clinical trials
Cytarabine
Cytarabine - administration & dosage
Daunorubicin
Daunorubicin - administration & dosage
Death
Drug dosages
Enzyme inhibitors
Female
fms-Like Tyrosine Kinase 3 - genetics
Humans
Induction therapy
Inhibitor drugs
Kaplan-Meier Estimate
Kinases
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - mortality
Male
Medical prognosis
Medical research
Middle Aged
Mutation
Myeloid leukemia
Oncology
Patients
Point mutation
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Protein-tyrosine kinase
Remission
Staurosporine - administration & dosage
Staurosporine - adverse effects
Staurosporine - analogs & derivatives
Survival
Transplantation
Young Adult
Online AccessGet full text

Cover

More Information
Summary:Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation, the addition of midostaurin to standard chemotherapy appeared to improve long-term outcomes.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1614359